CN114711428B - 果胶ecg组合物在抑制胃肠道吡啶类衍生物形成中的应用 - Google Patents
果胶ecg组合物在抑制胃肠道吡啶类衍生物形成中的应用 Download PDFInfo
- Publication number
- CN114711428B CN114711428B CN202210375131.2A CN202210375131A CN114711428B CN 114711428 B CN114711428 B CN 114711428B CN 202210375131 A CN202210375131 A CN 202210375131A CN 114711428 B CN114711428 B CN 114711428B
- Authority
- CN
- China
- Prior art keywords
- pectin
- ecg
- pyridine derivatives
- application
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001814 pectin Substances 0.000 title claims abstract description 46
- 229920001277 pectin Polymers 0.000 title claims abstract description 46
- 235000010987 pectin Nutrition 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 150000003222 pyridines Chemical class 0.000 title abstract description 31
- 230000002401 inhibitory effect Effects 0.000 title abstract description 14
- 230000015572 biosynthetic process Effects 0.000 title abstract description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 6
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- 229940040387 citrus pectin Drugs 0.000 claims description 3
- 239000009194 citrus pectin Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 5
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940015043 glyoxal Drugs 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 2
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- -1 flavanol compound Chemical class 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 229920000869 Homopolysaccharide Polymers 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/231—Pectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了果胶ECG组合物在抑制胃肠道吡啶类衍生物形成中的应用，属于保健食品或药品领域。本发明发现果胶与ECG组合使用后能显著提升胃肠道中抑制吡啶类衍生物形成的效果，且两者组合的抗氧化能力显著强于单独的果胶或ECG。果胶与ECG或含果胶与ECG的组合物可用于制备抑制吡啶类衍生物形成或抗氧化或治疗、延缓或改善吡啶类衍生物相关疾病的保健食品或药品，在抗氧化、抗衰老、抗糖尿病等领域具有广泛的应用前景。
Description
技术领域
本发明属于保健食品或药品领域，涉及果胶ECG组合物在抑制胃肠道吡啶类衍生物形成中的应用。
背景技术
在食品加工过程中发生的美拉德反应虽然可以提升食品的风味和品质，但也会生成大量的有害物质，具有一定的毒性和致癌性。吡啶类衍生物是美拉德反应产物的一种，是两个赖氨酸残基之间的交联体。与各类慢性疾病密切相关，在体内积聚会引发糖尿病的各种并发症。可以通过抑制吡啶类衍生物的形成来减少美拉德反应产物对人体的危害，从而延缓衰老，降低糖尿病等各种慢性疾病风险。
果胶是一种多糖，其组成有同质多糖和杂多糖两种类型。它们多存在于植物细胞壁和细胞内层，大量存在于柑橘、柠檬、柚子等果皮中。果胶作为一种高档的天然食品添加剂和保健品，可广泛应用于食品、医药保健品和一些化妆品中。国内果胶资源丰富，但加工利用率低，大部分原料都被直接丢弃，如能加以综合利用，将会带来巨大的经济效应。果胶作为一种天然的植物胶体，可作为一种胶凝剂、稳定剂、组织形成剂、乳化剂和增稠剂广泛应用于食品工业中；而果胶也是一种水溶性的膳食纤维，具有增强胃肠蠕动，促进营养吸收的功能，对防治腹泻、肠癌、糖尿病、肥胖症等病症有较好的疗效，是一种优良的药物制剂基质。
表儿茶素没食子酸酯（（-）-Epicatechin gallate，ECG）是一种天然植物黄烷醇化合物，具有抗氧化、清除自由基、加强新陈代谢、调节免疫和抗肿瘤等功能，同时还有诸多光谱抑菌效果，被认为具有极大的疾病预防潜力。
发明内容
本发明的目的在于提供果胶ECG组合物在抑制胃肠道吡啶类衍生物形成中的应用。
本发明的目的通过下述技术方案实现：
本发明发现果胶、ECG在胃肠道中能抑制吡啶类衍生物形成，果胶与ECG组合使用后能显著提升胃肠道中抑制吡啶类衍生物形成的效果，且两者组合的抗氧化能力显著强于单独的果胶或ECG。基于该发现，果胶与ECG或含果胶与ECG的组合物具有抑制胃肠道吡啶类衍生物形成的应用。果胶与ECG或含果胶与ECG的组合物具有制备抗氧化的保健食品或药品的应用。
进一步的，果胶与ECG或含果胶与ECG的组合物具有制备抑制吡啶类衍生物形成或制备治疗、延缓或改善吡啶类衍生物相关疾病的保健食品或药品的应用。所述的吡啶类衍生物相关疾病包括糖尿病、阿尔茨海默病、动脉粥样硬化等疾病。
一种抑制吡啶类衍生物形成或抗氧化或治疗、延缓或改善吡啶类衍生物相关疾病的保健食品或药品，包含果胶和ECG。
在一些实施方案中，所述的果胶为柑橘果胶。
本发明的有益效果在于果胶ECG组合物比单独的果胶或者ECG具有更强的抗氧化能力，并且在胃肠道抑制吡啶类衍生物生成的效果更显著。
本发明的果胶ECG组合物在胃肠道表现出显著的抗吡啶类衍生物生成作用和极强的自由基清除能力，在抗氧化、抗衰老、抗糖尿病等领域具有广泛的应用前景。
附图说明
图1是胃肠消化阶段不同样品的吡啶类衍生物抑制率。
图2是不同样品的DPPH自由基清除率。
图1-图2中，a-c不同字母表示差异有统计学意义（p<0.05）。
具体实施方式
以下实施例用于进一步说明本发明，但不应理解为对本发明的限制。若未特别指明，实施例中所用的技术手段为本领域技术人员所熟知的常规手段。
下述实施例中所使用的果胶为柑橘果胶购于默克生命科学技术(南通)有限公司。
下述实施例中所使用的ECG购于成都德思特生物技术有限公司。
下述实施例中所配制的相关溶液，如未说明均为用水配制。
实施例1：吡啶类衍生物生成抑制剂筛选
（1）在4 mL人工唾液（simulated salivary fluid，SSF，配制方法见表1）储备液中分别加入ECG、果胶、果胶ECG组合物（果胶ECG质量比1∶1），终浓度保持在0.3 g/L。再加入25µL 0.3 mol/L的CaCl2、加超纯水补至5 mL。加入200 mg牛血清白蛋白（bovine serumalbumin，BSA）、11.36 µL 8.8 mol/L的乙二醛（glyoxal，GO），建立牛血清白蛋白-乙二醛模型。混匀2分钟，作为口腔组。对照组不含ECG、果胶、果胶ECG组合物。
表1 模拟消化液原液的制备
（2）在步骤（1）中加入3.75 mL人工胃液（simulated gastric fluid，SGF，配制方法见表1）储备液，用0.1 mol/L HCl溶液调pH值至2.0。然后加入0.25 mL胃蛋白酶（80000U/mL）、2.5 µL 0.3 mol/L的CaCl2，最后加超纯水补至10 mL，在37℃恒温振荡箱内进行消化2 h，作为胃消化组。
（3）在步骤（2）中加入5.5 mL人工肠液（simulated intestinal fluid，SIF，配制方法见表1）储备液，然后加入2.5 mL胰酶（800 U/mL）、1.25 mL新鲜猪胆盐（160 mmol/L）、20 µL 0.3 M CaCl2，用NaOH（1 mol/L）调pH值至中性灭酶。用超纯水补至20 mL，置于37℃恒温振荡箱内进行消化2 h，消化结束后煮沸灭酶，作为肠消化组。
（4）采用BSA-GO模型，用日立F-4700荧光分光光度计在激发波长（λex）=366 nm和发射波长（λem）=442 nm处的荧光强度测定样品不同阶段吡啶类衍生物的含量。
吡啶类衍生物抑制率（%）=（1-A样/A对照）×100%
结果见图1，图1为胃肠消化阶段不同样品的吡啶类衍生物抑制率图，横坐标代表消化阶段，纵坐标代表吡啶类衍生物抑制率。口腔阶段对吡啶类衍生物的抑制率较低，从胃阶段开始，样品对吡啶类衍生物抑制效果增强。在胃阶段和肠阶段，果胶和ECG都可以抑制吡啶类衍生物生成，但果胶和ECG的吡啶类衍生物抑制率均弱于果胶ECG组合物，说明在胃肠消化阶段果胶ECG组合物在抑制吡啶类衍生物生成上有协同作用。
实施例2：1,1-diphenyl-2-picrylhydrazyl（DPPH）自由基清除率
方法如下：
（1）将上述用水稀释2倍后的肠消化组样品溶液0.2 mL与3.8 mL 0.1 mmol/LDPPH乙醇溶液混合，作为样品组。
（2）将上述用水稀释2倍后的肠消化组样品溶液0.2 mL与3.8 mL乙醇溶液混合，作为对照组。
（3）将0.2 mL H2O与3.8 mL 0.1 mmol/L DPPH乙醇溶液混合，作为空白组。
（4）将0.2 mL H2O与3.8 mL乙醇溶液混合，用来调零。
（5）将步骤（1）、（2）、（3）、（4）各组溶液放入黑暗条件下反应30 min。
（6）用酶标仪测定各组反应液在波长517 nm处的吸光值，样品组、对照组、空白组数据均需减去调零。
DPPH自由基清除能力（%）=[1-(A样-A对照）/A空白]×100%。
结果如图2所示，果胶的DPPH自由基清除率为20.62%，ECG的DPPH自由基清除率为37.56%，果胶ECG组合物的DPPH自由基清除率为59.46%。该组合物的DPPH自由基清除能力强于ECG和果胶的DPPH自由基清除能力，说明ECG和果胶在清除DPPH自由基方面具有协同作用。
以上所述仅表达了本申请的具体实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本申请技术方案构思的前提下，还可以做出若干变形和改进，这些都属于本申请的保护范围。
Claims (3)
1.一种抗氧化的组合物，其特征在于：由果胶和ECG组成，果胶和ECG的质量比为1:1。
2.根据权利要求1所述的组合物，其特征在于：所述的果胶为柑橘果胶。
3.权利要求1或2所述的组合物在制备抗氧化的保健食品或药品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210375131.2A CN114711428B (zh) | 2022-04-11 | 2022-04-11 | 果胶ecg组合物在抑制胃肠道吡啶类衍生物形成中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210375131.2A CN114711428B (zh) | 2022-04-11 | 2022-04-11 | 果胶ecg组合物在抑制胃肠道吡啶类衍生物形成中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114711428A CN114711428A (zh) | 2022-07-08 |
| CN114711428B true CN114711428B (zh) | 2023-09-22 |
Family
ID=82244357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210375131.2A Active CN114711428B (zh) | 2022-04-11 | 2022-04-11 | 果胶ecg组合物在抑制胃肠道吡啶类衍生物形成中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114711428B (zh) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002027957A (ja) * | 2000-07-17 | 2002-01-29 | Mitsui Norin Co Ltd | 植物ポリフェノール含有液体組成物 |
| JP2006028090A (ja) * | 2004-07-16 | 2006-02-02 | Taiyo Kagaku Co Ltd | 最終糖化産物生成阻害組成物 |
| US20070167395A1 (en) * | 2006-01-17 | 2007-07-19 | Isaac Eliaz | Compositions and methods for treating diabetes |
| JP2009055906A (ja) * | 2007-08-03 | 2009-03-19 | Kao Corp | 容器詰飲料 |
| CN103070400A (zh) * | 2012-07-17 | 2013-05-01 | 华中农业大学 | 莲原花青素作为晚期糖基化终产物形成抑制剂的用途 |
| CN103416826A (zh) * | 2012-05-14 | 2013-12-04 | 刘佩琴 | 一种无毒天然保鲜剂 |
| JP2020037540A (ja) * | 2018-09-05 | 2020-03-12 | 株式会社 伊藤園 | 認知機能の維持又は軽度認知障害の改善のための緑茶組成物 |
| JP2020036561A (ja) * | 2018-09-05 | 2020-03-12 | 株式会社 伊藤園 | 作業負荷に伴う認知機能低下の抑制のための緑茶組成物 |
| CN113925168A (zh) * | 2021-10-28 | 2022-01-14 | 湖北工业大学 | EGCG醌作为抗AGEs在胃肠道释放的抑制剂的应用 |
-
2022
- 2022-04-11 CN CN202210375131.2A patent/CN114711428B/zh active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002027957A (ja) * | 2000-07-17 | 2002-01-29 | Mitsui Norin Co Ltd | 植物ポリフェノール含有液体組成物 |
| JP2006028090A (ja) * | 2004-07-16 | 2006-02-02 | Taiyo Kagaku Co Ltd | 最終糖化産物生成阻害組成物 |
| US20070167395A1 (en) * | 2006-01-17 | 2007-07-19 | Isaac Eliaz | Compositions and methods for treating diabetes |
| JP2009055906A (ja) * | 2007-08-03 | 2009-03-19 | Kao Corp | 容器詰飲料 |
| CN103416826A (zh) * | 2012-05-14 | 2013-12-04 | 刘佩琴 | 一种无毒天然保鲜剂 |
| CN103070400A (zh) * | 2012-07-17 | 2013-05-01 | 华中农业大学 | 莲原花青素作为晚期糖基化终产物形成抑制剂的用途 |
| JP2020037540A (ja) * | 2018-09-05 | 2020-03-12 | 株式会社 伊藤園 | 認知機能の維持又は軽度認知障害の改善のための緑茶組成物 |
| JP2020036561A (ja) * | 2018-09-05 | 2020-03-12 | 株式会社 伊藤園 | 作業負荷に伴う認知機能低下の抑制のための緑茶組成物 |
| CN113925168A (zh) * | 2021-10-28 | 2022-01-14 | 湖北工业大学 | EGCG醌作为抗AGEs在胃肠道释放的抑制剂的应用 |
Non-Patent Citations (2)
| Title |
|---|
| Wu, CH 等.Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts.JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY.2005,第53卷(第8期),第3167-3173页. * |
| 刘娜等.果胶的生物活性及其用于包装材料的研究进展.食品工业科技.2021,(第6期),第348-356页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114711428A (zh) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stanisavljević et al. | Antioxidant and antiproliferative activity of chokeberry juice phenolics during in vitro simulated digestion in the presence of food matrix | |
| Zhang et al. | Inhibitory effect of chestnut (Castanea mollissima Blume) inner skin extract on the activity of α-amylase, α-glucosidase, dipeptidyl peptidase IV and in vitro digestibility of starches | |
| Gebru et al. | Nutritional composition and health benefits of teff (Eragrostis tef (Zucc.) Trotter) | |
| CN102630948A (zh) | 一种高纤无糖果味型复合益生元及其制备方法 | |
| EP3655520B1 (de) | Sequentielles co-kultivierungsverfahren zur herstellung eines vitamin- und proteinreichen nahrungsmittels | |
| Bae et al. | ANTIOXIDANT AND IMMUNO‐MODULATING ACTIVITIES OF KOREAN TRADITIONAL RICE WINE, TAKJU | |
| Chen et al. | Enhancing organic selenium content and antioxidant activities of soy sauce using nano-selenium during soybean soaking | |
| Irondi et al. | Effect of endogenous lipids and proteins on the antioxidant, in vitro starch digestibility, and pasting properties of sorghum flour | |
| He et al. | Effects of two contrasting dietary polysaccharides and tannic acid on the digestive and physicochemical properties of wheat starch | |
| Tan et al. | In vitro simulated digestion of and microbial characteristics in colonic fermentation of polysaccharides from four varieties of Tibetan tea | |
| CN114711428B (zh) | 果胶ecg组合物在抑制胃肠道吡啶类衍生物形成中的应用 | |
| EP2668850B1 (fr) | Complément alimentaire solide pour sandwich, procédé de fabrication et sandwich comprenant un tel complément alimentaire solide | |
| WO2007140277A1 (en) | Method for embedding and targeted release of micronutrients in activated dietary fibers | |
| WO2023216951A1 (zh) | 一种抗衰老的含有尿苷酸、腺苷酸和酵母肽的组合物及其应用 | |
| CN104543635B (zh) | 一种虾红素胶原蛋白果冻 | |
| Akhtar et al. | Digestion by saliva, simulated gastric and small intestinal juices and in vitro fermentation by human gut microbiota of polysaccharides from cicer arietinum L. hulls: Chickpea hull polysaccharide effect on human gut | |
| EP4268602A1 (en) | Method for producing rice protein-containing liquid composition | |
| CN114712384B (zh) | 壳聚糖egcg组合物在抑制胃肠道交联素形成中的应用 | |
| Liu et al. | Effects of steam explosion on the nutritional and functional properties of black‐grained wheat bran and its application | |
| CN114698844A (zh) | 壳聚糖原花青素组合物在抑制胃肠道戊糖素形成中的应用 | |
| Li et al. | Prebiotic characteristics of added-value polysaccharides from jackfruit peel waste during in vitro digestion and fecal fermentation | |
| KR102386213B1 (ko) | 저염 새우젓의 제조방법 | |
| CN113498838A (zh) | 一种蜜炼陈皮柑汁膏及其制备方法 | |
| Tang et al. | Digestibility of indica rice and structural changes of rice starch during fermentation by Lactobacillus plantarum | |
| CN104543820A (zh) | 红枣酥及其制造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |